Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome
Maro Ohanian, Christian Cable, Kathleen HalkaDepartment of Hematology and Oncology, Scott and White Healthcare, The Texas A&M Health Science Center College of Medicine, Temple, TX, USAAbstract: This case report describes how eculizumab reversed neurologic impairment and improved renal da...
Guardado en:
Autores principales: | Ohanian M, Cable CC, Halka KK |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/65e2b59bd0324ba0b6de9db31e3d079a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report
por: Halka K, et al.
Publicado: (2011) -
Uncommon presentation of atypical hemolytic uremic syndrome: A Case Report
por: Sandra M Martin, et al.
Publicado: (2021) -
Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort.
por: Hong Si Nga, et al.
Publicado: (2021) -
Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort
por: Hong Si Nga, et al.
Publicado: (2021) -
SOLUBLE ADHESION MOLECULES IN CHILDREN WITH HEMOLYTIC UREMIC SYNDROME
por: T. E. Pankratenko, et al.
Publicado: (2018)